NCT01031992

Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: University Hospital, Saarland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can 1. improve anemia (lead to an increased hemoglobin level) 2. reduce nosebleeds.

Conditions

• Hereditary Hemorrhagic Telangiectasia

Interventions

Type	Name	Description
DRUG	Tranexamic acid first, than placebo	For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
DRUG	First placebo, than Tranexamic acid.	First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.

Timeline

• Start date: 2002-03-01
• Primary completion: 2002-08-01
• Completion: 2002-10-01
• First posted: 2009-12-15
• Last updated: 2009-12-15

Locations

1 site across 1 country: Germany